Evaluation of the Dietary Supplement Effect on Improvement of Hair Condition in Subjects With Occasional Hair Loss.

NCT07835646 | Not Yet Recruiting

• 1 other identifier: CT26786
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to learn if dietary supplement works to help with improving hair condition in subjects with occasional hair loss. It will also learn about its safety. The main question it aims to answer is:

• Does the dietary supplement reduce the number of hair lost by participants? Researchers will compare dietary supplement to a placebo (a look-alike substance that contains no drug) to see if it works to reduce hair loss. Participants will:
• Take dietary supplement or a placebo every day for 3 months
• Visit the clinic every month for evaluations

Conditions

Occasional Hair Loss

Outcome Measures

Primary Outcomes (1)

• Change from Baseline in the number of shed hairs at 3 Months

  Hair loss will be evaluated by wash and combing test

  From enrollment to the end of treatment at 3 months

Study Arms (2)

Dietary supplement capsule

EXPERIMENTAL

Dietary Supplement: Dietary supplement for hair loss

Placebo capsule

PLACEBO COMPARATOR

Other: Placebo

Interventions

Dietary supplement for hair loss DIETARY_SUPPLEMENT

Dietary supplement will be taken daily for 2 months

Dietary supplement capsule

Placebo OTHER

Placebo will be taken daily for 2 months

Placebo capsule

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men and women aged 18 to 70 years.
• Self-perceived occasional telogen effluvium, with a count of 100 or more shed hairs in the standardized wash and combing test, confirmed at the screening visit (Visit 0), of recent onset (less than 6 months) and attributable to factors such as stress, nutritional deficiency, pollution, or seasonality.
• Good general health, in the investigator's judgment, with no relevant uncontrolled systemic disease.
• Availability and willingness to attend the three study visits and comply with study procedures over a 90-day period.
• Agreement to receive study-related communications electronically (email and/or SMS), where expressly authorized.
• Ability to understand the study and provide written informed consent.

You may not qualify if:

• Refusal to provide informed consent to participate in the study.
• Inability to understand the study language.
• Pregnancy or breastfeeding.
• Established androgenetic alopecia (Hamilton-Norwood classification or other pattern hair loss disorders) or other forms of alopecia (alopecia areata, scarring alopecia, trichotillomania, or others) diagnosed or suspected by the investigator.
• Use of specific pharmacological or cosmetic treatments for hair loss (minoxidil, finasteride, topical or systemic corticosteroids, other dietary supplements, or hair lotions) within the 3 months prior to enrollment.
• Uncontrolled endocrine disease (e.g., thyroid disorders), diagnosed severe nutritional deficiency, untreated anemia, or a recent history (\< 6 months) of severe febrile illness, major surgery, or childbirth.
• Active scalp dermatological conditions (psoriasis, moderate-to-severe seborrheic dermatitis, fungal or bacterial infections) that may interfere with clinical assessment or instrumental evaluation techniques.
• Any disease, treatment, or characteristic that, in the investigator's opinion, may preclude participation due to unnecessary risk or interference with the study and/or interpretation of the results, particularly:
• Use of aspirin or related compounds, antibiotics, anti-inflammatory drugs, corticosteroids, antidepressants, antihistamines, or immunosuppressive treatments.
• Ongoing allergen desensitization therapy (allergy immunotherapy).
• Presence of dermatological abnormalities in the study area, such as irritation, erythema, scars, pigmentation disorders, numerous freckles, or nevi.
• History of intolerance or allergy to medications or other substances that may pose an unjustified risk.
• Use of a nutricosmetic supplement within the 3 months prior to study initiation or during the entire study period.
• History of intolerance or allergy to cosmetic products of the same type as the investigational product.
• Receipt of a vaccination within the previous month or planned vaccination during the study period.

Sponsors & Collaborators

• Lacer S.A.: lead

Study Sites (1)

Cosmocare

Barcelona, Spain

Location

MeSH Terms

Interventions

Dietary Supplements

Intervention Hierarchy (Ancestors)

Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Central Study Contacts

Chávez Bourgeois, Dr.

CONTACT

+34 937 37 64 00; marionminisa@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 17, 2026
• First Posted: September 23, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): February 1, 2027
• Last Updated: September 23, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)